Skip to main content
main-content

17.09.2016 | Original Article | Ausgabe 11/2016

Tumor Biology 11/2016

Association between XRCC3 Thr241Met polymorphism and nasopharyngeal carcinoma risk: evidence from a large-scale case-control study and a meta-analysis

Zeitschrift:
Tumor Biology > Ausgabe 11/2016
Autoren:
Qian Cui, Xiao-Yu Zuo, Yi-Fan Lian, Qi-Sheng Feng, Yun-Fei Xia, Cai-Yun He, Li-Zhen Chen, Wei-Hua Jia, Hai-Qiang Mai, Yi-Xin Zeng, Jin-Xin Bei
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-016-5300-y) contains supplementary material, which is available to authorized users.
Qian Cui and Xiao-Yu Zuo equally contributed to the work.
Yi-Xin Zeng and Jin-Xin Bei jointly supervised the work.

Abstract

The X-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism (rs861539, C > T) has drawn wide attentions as its association with cancer risk and its involvement in DNA repair. Several studies have attempted to link rs861539 to nasopharyngeal cancer (NPC) risk; however, the sample sizes of these studies are small and the results are controversial. To investigate the relationship of rs861539 and NPC susceptibility, we conducted a large-scale case-control study involving 4001 NPC cases and 2967 controls of southern Chinese. Logistic regression analysis revealed significant association for rs861539 and NPC risk under the recessive model (TT vs. CT + CC) with adjustment of age and gender (odds ratio, OR = 2.72; 95 % CI 1.10–6.72; P = 0.03). Further, meta-analysis involving 4457 NPC cases and 4132 controls from four studies showed consistent association of TT carriers and NPC risk (OR = 3.12; 95 % CI 1.58–6.13; P = 0.001). Taken together, our findings based on large-scale sample size suggested rs861539 at XRCC3 to be associated with NPC risk through recessive model.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2016

Tumor Biology 11/2016Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.